| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Grants and contracts | ||||||||||
922 | 1,138 | - | - | - | - | - | - | - | - | - |
Grants and contracts | ||||||||||
- | - | 1,948 | 3,518 | 2,708 | 3,701 | 8,487 | 3,570 | 8,790 | 15,331 | 12,695 |
Operating expenses: | ||||||||||
Service | ||||||||||
- | - | - | - | - | - | - | - | - | - | 1,650 |
Total revenues | ||||||||||
- | - | - | - | - | - | - | - | - | - | 14,345 |
Research and development | ||||||||||
1,656 | 3,619 | 5,048 | 6,496 | 7,143 | 9,654 | 19,525 | 22,501 | 22,788 | 16,141 | 14,331 |
General and administrative | ||||||||||
1,817 | 2,318 | 2,500 | 3,378 | 6,355 | 8,469 | 12,038 | 11,115 | 11,106 | - | 6,397 |
General and administrative | ||||||||||
- | - | - | - | - | - | - | - | - | 9,927 | - |
Total operating expenses | ||||||||||
3,474 | 5,938 | 7,549 | 9,874 | 13,499 | 18,123 | 31,564 | 33,617 | 33,895 | 26,068 | 20,728 |
Loss from operations | ||||||||||
-2,552 | -4,799 | -5,600 | -6,355 | -10,791 | -14,421 | -23,076 | -30,046 | -25,105 | -10,737 | -6,382 |
Other income (expense): | ||||||||||
Other expense | ||||||||||
- | - | - | - | - | - | - | - | - | - | 195 |
Change in value of warrant liability | ||||||||||
- | - | - | - | - | - | - | - | - | - | -6,267 |
Interest and other income (expense) | ||||||||||
-681 | 126 | 197 | 263 | -99 | -1,089 | 44 | 295 | 53 | - | -6,443 |
Interest and other income | ||||||||||
- | - | - | - | - | - | - | - | - | - | 19 |
Foreign exchange gain (loss) | ||||||||||
-1 | 3 | -13 | 362 | -509 | -1,036 | 38 | -365 | - | - | - |
Gain on investment provision | ||||||||||
- | - | - | 40 | -1,060 | - | - | - | - | - | - |
Investment loss provision | ||||||||||
- | - | - | - | - | 0 | - | - | - | - | - |
Gain on deconsolidation of Incuron, LLC | ||||||||||
- | - | - | - | - | 14,206 | - | - | - | - | - |
Change in value of warrant liability | ||||||||||
-72 | -962 | 4,426 | -3,099 | 221 | -2,662 | -2,864 | -7,701 | -19,821 | - | - |
Equity in loss of Incuron, LLC | ||||||||||
- | - | - | - | -362 | -285 | - | - | - | - | - |
Interest and other income (expense) | ||||||||||
- | - | - | - | - | - | - | - | - | 77 | - |
Change in value of warrant liability | ||||||||||
- | - | - | - | - | - | - | - | - | 16,011 | - |
Total other income (expense) | ||||||||||
-610 | 1,092 | -4,241 | 3,765 | -2,253 | 14,457 | 2,947 | 7,631 | 19,875 | -15,934 | - |
Net loss | ||||||||||
-3,162 | -3,707 | -9,842 | -2,590 | -13,044 | 35 | -20,129 | -22,414 | -5,229 | -26,671 | -12,826 |
Net loss | ||||||||||
-3,162 | -3,707 | -9,842 | -2,590 | - | - | - | - | -5,229 | -26,671 | -12,826 |
Net loss attributable to noncontrolling interests | ||||||||||
-47 | -95 | -136 | 68 | -407 | -1,593 | -2,866 | -4,180 | -1,216 | 305 | - |
Dividends on convertible preferred stock | ||||||||||
- | - | - | - | - | - | - | - | - | - | -615 |
Net loss attributable to Cleveland BioLabs, Inc. | ||||||||||
- | - | -9,706 | -2,658 | -12,637 | 1,629 | -17,262 | -18,234 | -4,013 | - | -13,441 |
Net loss attributable to Cleveland BioLabs, Inc. | ||||||||||
-3,114 | -3,611 | - | - | - | - | - | - | - | -26,366 | -12,826 |
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share) | ||||||||||
-0.28 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -0.12 | - | -0.82 |
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares) | ||||||||||
11,298 | 11,293 | 11,192 | 10,987 | 7,060 | 2,702 | 2,250 | 1,869 | 32,561 | - | - |
Net loss available to common stockholders per share of common stock, basic and diluted (in Dollars per share) | ||||||||||
- | - | - | - | - | - | - | - | - | -1.01 | - |
Weighted average number of shares used in calculating net loss per share, basic and diluted (in Shares) | ||||||||||
- | - | - | - | - | - | - | - | - | 26,184 | - |
Weighted average number of shares used in calculating net loss per share, basic and diluted (in Shares) | ||||||||||
- | - | - | - | - | - | - | - | - | - | 16,405 |